Pfizer Inc., Johnson & Johnson Scrap Alzheimer's Drug After Phase III Study Fails
(Reuters) - Pfizer Inc and Johnson & Johnson said they were scrapping further studies of one of the most anticipated experimental Alzheimer's disease treatments after the drug failed to help patients with the memory-robbing condition in a second high-profile late stage clinical trial.